Financial Data and Key Metrics Changes - Total revenue for the year ended December 31, 2025, was $3.09 million, a decrease from $3.5 million in 2024, primarily due to lower R&D collaboration activity and reduced license and milestone revenue, partially offset by a $1.86 million increase in grant revenue from the Gates Foundation and CEPI [19][20] - Cost of R&D revenue declined to $0.6 million in 2025 from $1.2 million in 2024, while internal R&D expenses increased modestly to $2.16 million in 2025 from $2.04 million in 2024 [19][20] - Net loss was $7.36 million or $0.23 per share compared to a net loss of $5.81 million or $0.20 per share in 2024 [20] Business Line Data and Key Metrics Changes - Life sciences is the most advanced business line, focusing on recombinant animal-free proteins for cell culture media and molecular biology workflows, with significant market demand [5][10] - The company launched recombinant human albumin in early 2026, which is expected to generate recurring revenue through a profit-sharing arrangement with Proliant Health & Biologicals [7][10] - The food and nutrition segment is expanding with agreements to develop animal-free recombinant bovine alpha-lactalbumin and human lactoferrin, targeting global health and nutrition markets [11][12] Market Data and Key Metrics Changes - The life sciences market is shifting towards recombinant, high-quality, and scalable alternatives to traditional animal-derived inputs, which aligns with the company's production platforms [5][10] - The demand for animal-free proteins and functional ingredients is increasing globally, driven by sustainability trends [10][11] Company Strategy and Development Direction - The company aims to transition from a development stage platform to a commercial product-driven biotechnology business with multiple revenue paths [4] - Strategic partnerships, such as with Fermbox and IBT Bioservices, are crucial for scaling manufacturing and market penetration [13][14] - The focus is on executing product sales in life sciences, advancing partner-led programs in food and nutrition, and expanding bioindustrial applications [72] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the transition phase reflected in current financials but emphasizes significant advancements towards commercialization and product launches [4][72] - The company expects increasing repeat orders and revenue growth through 2026 and beyond as products move into routine use [10][72] - Management is optimistic about the potential for new product launches and collaborations to drive future revenue [21][72] Other Important Information - The company has approximately $8.6 million in cash equivalents and plans disciplined cash usage while prioritizing high-impact R&D programs [21][22] - An ATM facility has been established for flexibility in accessing capital, allowing the company to be proactive in favorable market conditions [22] Q&A Session Summary Question: Timing and ramp of product revenues - Management anticipates a slow ramp in product revenues as products need to be qualified for use in customer workflows, with a focus on signing more distribution agreements for larger volume opportunities [25][27] Question: Upfront license fees in collaborations - The potential for upfront license fees depends on the product and market stage, with a push for larger fees for more developed products [28][30] Question: Internal changes to manage new partnerships - The expansion of partnerships enhances internal capabilities, with partners like Fermbox and IBT providing dedicated sales and manufacturing support [36][37] Question: Control over pricing - Pricing control varies by product and market, with greater flexibility in segments where the company has more control over the product [38][40] Question: Breakeven timeline - Management aims to achieve breakeven as quickly as possible but emphasizes the importance of making decisions that are in the best long-term interest of the company [46][47] Question: Impact of energy environment on cultured food - Regulatory scrutiny and consistency in production are significant factors driving the shift towards non-animal proteins, alongside energy considerations [51][53] Question: Opportunities in biopharmaceuticals - The company sees opportunities beyond pandemic preparedness, with potential for seasonal vaccines and other health needs [58][60] Question: Grant revenue recognition - Grant revenue is recognized based on the percentage of completion of the project, not on a straight-line basis [61]

Financial Data and Key Metrics Changes - Total revenue for the year ended December 31, 2025, was $3.09 million, a decrease from $3.5 million in 2024, primarily due to lower R&D collaboration activity and reduced license and milestone revenue, partially offset by a $1.86 million increase in grant revenue from the Gates Foundation and CEPI [19][20] - Loss from operations increased to $7.19 million in 2025 from $5.9 million in the prior year, with a net loss of $7.36 million or $0.23 per share compared to a net loss of $5.81 million or $0.20 per share in 2024 [20] Business Line Data and Key Metrics Changes - The life sciences segment is the most advanced, focusing on recombinant animal-free proteins for cell culture media and molecular biology workflows, with significant progress in product launches and partnerships [5][9] - Recombinant human albumin was commercially launched in early 2026, marking a significant milestone in the life sciences portfolio [6] - The food and nutrition segment is expanding with a focus on sustainable animal-free proteins, including a partnership with BRIG BIO to develop recombinant bovine alpha-lactalbumin [10][11] Market Data and Key Metrics Changes - The markets for recombinant proteins are shifting towards animal-free alternatives, driven by demand in biologic manufacturing, cell and gene therapy, and cultivated meat [5][9] - The global shift towards sustainable animal-free proteins and functional ingredients is creating significant opportunities in the food and nutrition sector [9][10] Company Strategy and Development Direction - The company is transitioning from a development stage to a commercial product-driven biotechnology business, focusing on multiple revenue paths and strengthening technological capabilities through partnerships [4] - The strategy includes leveraging the Dapibus platform for large-scale production and forming partnerships with established companies for market access [9][10] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of execution in scaling product sales and advancing partner-led programs, with expectations for increasing conversion into product sales and repeat orders through 2026 and beyond [71] - The company is focused on maintaining disciplined cash usage while prioritizing high-impact R&D programs and anticipates growth in product revenues across life sciences and food and nutrition markets [21][22] Other Important Information - The company has established an ATM facility for flexible capital access, allowing it to respond to favorable market conditions without being forced into larger transactions [22] - The collaboration with Fermbox Bio is crucial for scaling technology into large volume applications, providing access to commercial scale manufacturing [13][14] Q&A Session Summary Question: Timing and ramp of product revenues - Management indicated a slow ramp in product revenues as products need to be qualified for use in workflows, with expectations for significant growth as companies become accustomed to the products [24][25] Question: Upfront license fees in collaborations - The response highlighted that the potential for upfront fees depends on the product and market stage, with efforts to secure larger upfront revenues for more developed products [27][29] Question: Internal changes to manage new partnerships - Management noted that expanding partnerships enhances internal capabilities, leveraging partners' dedicated teams for sales and manufacturing [34][36] Question: Pricing control in various arrangements - The company has visibility in partner-led programs but maintains margins through pre-established agreements, with flexibility in pricing depending on market sensitivity [37][39] Question: Breakeven timeline - Management acknowledged the difficulty in predicting breakeven but emphasized the goal of achieving revenue positivity as quickly as possible while ensuring long-term sustainability [44][45] Question: Impact of higher energy environment on cultured food - Management noted that regulatory scrutiny and consistency are driving shifts in the food space, with a growing demand for scalable non-animal proteins [49][52] Question: Grant revenue recognition - The CFO clarified that grant revenue is recognized based on the percentage of costs incurred for the entire project, rather than a straight-line basis [59][61]

Summary of Dyadic International Conference Call Company Overview - **Company**: Dyadic International (NasdaqCM: DYAI) - **Industry**: Life Sciences, specifically focusing on bioengineering proteins for therapeutic and non-therapeutic applications Key Points and Arguments 1. **Transition to Commercialization**: Dyadic has shifted from an R&D stage company to a commercial organization over the past three years, aiming to generate revenue through product launches [2][5][31] 2. **Rebranding and Focus**: The company rebranded to Dyadic Applied BioSolutions and is now focusing on product technology rather than platform technology, with an emphasis on commercializing products in shorter timeframes [4][31] 3. **Product Portfolio Development**: Dyadic has developed a portfolio of products that require less investment and time to commercialize, including the Dapibus platform for food and nutrition [4][6][10] 4. **Revenue Generation Strategy**: The revenue strategy is based on "buy, brand, and build," allowing direct sales, OEM white label sales, and licensing of strains to partners [11][13] 5. **Market Focus**: The company is targeting large and growing markets in life sciences, food and nutrition, and bioindustrial sectors, with specific advantages in producing non-animal proteins and enzymes at lower costs [13][14][15] 6. **Key Product Launches**: Dyadic has launched several products, including DNase I and AlbuFree DX, and is preparing to launch transferrin and growth factors [18][21][22] 7. **Partnerships**: Strategic partnerships with companies like Proliant Health and Biologicals and Inzymes are crucial for product launches and revenue generation [7][23][24] 8. **Pipeline and Future Products**: The company has a robust pipeline with upcoming products in both life sciences and food sectors, including human and bovine alpha-lactalbumin [21][26] 9. **Financial Expectations**: Initial revenues are expected from product sales and partnerships, with a goal to achieve a steady revenue run rate by layering product and partnership revenues [27][28][33] 10. **Regulatory Advantages**: Non-therapeutic products do not require FDA review, allowing for quicker commercialization compared to traditional therapeutic products [32] Additional Important Content - **CRISPR Technology**: The integration of CRISPR technology enhances the ability to optimize protein production, opening new product categories [35] - **Legacy Programs**: Ongoing legacy R&D programs are fully funded and will not detract from current revenue-generating efforts, serving as potential future revenue sources [30][31] - **Market Perception**: There is a belief that the market underestimates Dyadic's earning potential for 2026 and 2027, as the company is now positioned to generate significant revenues from its products [36][37] - **Strategic Shift**: The focus has shifted from licensing technology to generating direct revenues through product sales, indicating a more proactive approach to market engagement [38] This summary encapsulates the key insights from the Dyadic International conference call, highlighting the company's strategic direction, product development, and market positioning.

Summary of Dyadic International Conference Call - December 09, 2025 Company Overview - **Company**: Dyadic International (NasdaqCM:DYAI) - **Industry**: Biomanufacturing, Life Sciences, Food Nutrition, Bio-Industrial Markets - **Focus**: Scalable, animal-free recombinant protein solutions Key Points and Arguments 1. **Commercial Inflection Point**: Dyadic is at a significant commercial inflection point with multiple products entering the market and active revenue engines [2][4][30] 2. **Transition from R&D to Commercialization**: The company has shifted focus from R&D and grant-based revenues to commercial applications, particularly in non-therapeutic areas that do not require FDA review [3][5][30] 3. **Product Launch Timeline**: Dyadic expects multiple product launches starting in 2025 and continuing through 2027, with a focus on life sciences, food nutrition, and bio-industrial segments [4][10][32] 4. **Platform Technologies**: The company utilizes two main platforms, C1 and Dapibus, designed for speed, productivity, scale, and low cost, to produce recombinant animal-free protein solutions [7][9][30] 5. **Market Segments**: - **Life Sciences**: Focus on cell culture media, cell and gene therapy, and high-value proteins like human transferrin and albumin [11][15][19] - **Food Nutrition**: Targeting the alternative protein market, particularly non-animal dairy and functional food proteins, with a market size estimated at $50-$70 billion [12][22] - **Bio-Industrial**: Re-entering the market through partnerships, focusing on cellulosic enzymes with a market size of approximately $6 billion [13][14][23] 6. **Revenue Generation Strategy**: Dyadic employs a three-pillar strategy: buy, brand, and build, allowing for direct sales, licensing, and partnerships to monetize its technology [9][10][19] 7. **Partnerships**: Collaborations with companies like Proliant Health and Fermbox Bio are expected to drive revenue growth and product launches [16][23][29] 8. **Regulatory Advantages**: The focus on non-therapeutic products allows for faster market entry, with timelines of 12-18 months from proof of concept to revenue [5][18][31] 9. **Financial Projections**: The company anticipates meaningful revenue growth starting in early 2026, with a revenue run rate of approximately $12 million needed to reach cash flow positive status [33][37] Additional Important Information - **Innovation and Technology**: Dyadic has access to CRISPR technology, enhancing its ability to optimize production strains [4][30] - **Market Trends**: The shift towards sustainable and predictable proteins is driving demand for Dyadic's products, particularly in the context of growing consumer preference for non-animal sources [3][12] - **Future Outlook**: The company is positioned for significant growth with a layered revenue approach, leveraging existing partnerships and expanding its product portfolio [26][27][32] This summary encapsulates the key insights from the Dyadic International conference call, highlighting the company's strategic direction, market opportunities, and financial outlook.

Summary of Dyadic International Conference Call Company Overview - **Company**: Dyadic International (Ticker: DYAI) - **Industry**: Biotechnology, specifically focusing on recombinant proteins and enzymes for life sciences, food, nutrition, and bioindustrial applications - **Key Personnel**: Joe Hazelton, President and COO, with prior experience at Novartis Pharmaceuticals [2][3] Core Points and Arguments - **Strategic Shift**: Dyadic has transitioned from a platform-based organization to a product-focused company, emphasizing high-growth non-therapeutic markets to generate revenue more quickly and reliably [2][3][4] - **Technology Platforms**: The company utilizes two main platforms: - **C1 Adaptabus**: Focused on producing high-yield, animal-free recombinant proteins for life sciences and biopharmaceuticals [3][4] - **Dapivis**: Designed for food, nutrition, and bioindustrial markets, offering lower-cost production of proteins and enzymes [8][9] - **Market Opportunities**: Dyadic targets a total addressable market of approximately $25 billion across various sectors, including life sciences, food, nutrition, and bioindustrial applications [4][32] - **Revenue Generation**: The company is moving towards commercialization with initial revenue streams from partnerships and product launches expected in 2025 and beyond [11][12][35] Financial Projections - **Cash Flow Positive**: Dyadic anticipates becoming cash flow positive by the end of 2026, with a low annual burn rate of $4 million to $5 million [34][35] - **Revenue Ramp**: The company expects significant revenue growth driven by partnerships, particularly in the cell culture media market, which is projected to be a billion-dollar opportunity [36][37] Market Segments and Products - **Life Sciences**: Targeting a $10 billion market, focusing on cell culture media, diagnostics, and therapeutic proteins [8][12] - **Key Products**: Recombinant human albumin, transferrin, and growth factors, which are critical for biomanufacturing [14][15] - **Food and Nutrition**: Estimated at $11 billion, focusing on non-animal dairy and functional proteins [17][18] - **Partnerships**: Collaborations with companies like Enzymes for non-animal dairy enzymes, with expected product launches in late 2025 [17][28] - **Bioindustrial**: Aiming for a $100 billion market, focusing on enzymes for biomass conversion and other industrial applications [10][20] Competitive Advantages - **High Yield and Low Cost**: Dyadic's platforms are designed to produce high-quality, sustainable, and ethically sourced proteins at competitive costs, addressing the market shift towards non-animal solutions [6][32] - **Faster Time to Market**: The company emphasizes shorter development cycles compared to traditional biopharmaceuticals, allowing for quicker revenue generation [11][24] Partnerships and Collaborations - **Strategic Partnerships**: Dyadic has established partnerships with key players in the industry, such as Proliant Health and Biologicals, to leverage their distribution networks and expertise [13][36] - **Funding and Grants**: The company has secured funding from organizations like the Gates Foundation and is involved in initiatives like the European Vaccine Hub, which supports its biopharmaceutical programs [30][31] Conclusion - **Inflection Point**: Dyadic is at a critical juncture, transitioning from R&D reliance to active commercialization of products, with a strong focus on non-therapeutic markets that promise quicker revenue streams [33][34] - **Future Outlook**: The company is optimistic about its growth trajectory, with expectations of profitability within three years as it capitalizes on its innovative platforms and market opportunities [35][37]

Core Viewpoint - Dyadic International, Inc. is transitioning from a technology development organization to a market-facing, revenue-focused biotechnology company, with significant advancements in its life sciences and nutrition pipelines, and a recent capital raise to support this shift [2][4]. Company Developments and Updates - The company completed a strategic leadership and operational transformation, rebranding as Dyadic Applied BioSolutions to emphasize commercial execution [4]. - Dyadic raised $5.3 million through an equity offering to enhance liquidity and fund pipeline and commercial growth [4][11]. - As of June 30, 2025, the company reported cash and equivalents of $7.3 million, down from $9.3 million at the end of 2024 [10]. Financial Highlights - Total revenue for Q2 2025 reached $967,000, a significant increase from $386,000 in the same period last year, driven by milestone revenues [12][13]. - Research and development expenses rose to $629,000 from $516,000 year-over-year, reflecting increased internal research initiatives [14]. - General and administrative expenses decreased by 10.6% to $1,437,000 compared to $1,608,000 in the previous year [15]. - The net loss for Q2 2025 was $1,794,000, an improvement from a net loss of $2,045,000 in the same quarter of the previous year [17]. Product Development and Partnerships - Dyadic is advancing its recombinant serum albumin and transferrin products, with expected commercial launches in 2025 [5]. - The company is also developing additional nucleic acid enzymes to meet growing demand for DNA/RNA manipulation tools, with results anticipated by late 2025 [6]. - Dyadic has achieved milestones in its partnership with the Gates Foundation, receiving $1.5 million in funding for monoclonal antibody development [12]. Market Focus - Dyadic's microbial production platforms are positioned to disrupt the cost, speed, and scalability of protein production across various markets, particularly as industries shift towards non-animal sources [2][4]. - The company is actively negotiating licensing and supply agreements for its recombinant alpha-lactalbumin and expects to launch additional non-animal dairy enzymes by late 2025 [12].

Company Overview - Dyadic is a bioprocessing platform company transitioning from R&D to commercial revenue generation[4, 10, 24] - The company has two validated platforms, C1 and Dapibus, targeting life sciences, food/nutrition, and bio-industrial markets[4, 24] - Dyadic's market capitalization is $3009 million as of July 21, 2025, with approximately $74 million in cash and investment-grade securities as of March 31, 2025[62] Market Opportunity - The company is targeting a $25 billion+ market opportunity across key segments[7, 62] - The recombinant food & nutrition market is estimated at ~$11 billion in 2025[16, 31] - The cell culture media market is estimated at ~$5 billion in 2025, while the molecular biology reagents market is estimated at ~$2 billion in 2025[25, 27] - The recombinant bio-industrial enzymes market is estimated at ~$6 billion in 2025[16, 36] Commercial Strategy - Dyadic is focused on non-therapeutic applications for near-term revenue generation[4, 20, 62] - The company utilizes three revenue pathways: strain licensing, strategic partnerships, and direct product sales[42] - Initial revenue streams are active, with multiple non-therapeutic protein products expected to launch over the next 12-36 months[7, 24]

DNase I Oncology Platform - The company is focused on advancing its proprietary DNase I technology platform to address multiple high-value cancer indications[2, 5] - DNase I targets Neutrophil Extracellular Traps (NETs) to improve immunotherapies and chemotherapies[2, 5] - DNase I digests both double and single-stranded DNA, as well as DNA:RNA hybrids, exposing cancer cells to the immune system and reducing therapy resistance[6] - Systemic administration of DNase I improves the efficacy of PD-1 blockade, resulting in the lowest tumor volume growth compared to either DNase I or anti-PD-1 alone[19] Pipeline and Clinical Development - The company's lead program, XBIO-015, combines systemic DNase I with chemotherapy for pancreatic carcinoma[7] - A Phase 1 study is planned, featuring dose escalation and expansion in subjects with locally advanced or metastatic solid tumors, with pancreatic cancer and other solid tumor indications[2, 40] - The company believes that an ORR greater than 50% or PFS greater than 9 months would be a meaningful improvement to the current standard of care for pancreatic cancer[45] Market Opportunity - The company is initially targeting pancreatic carcinoma, a multi-billion-dollar indication with significant unmet need, with a projected market of $48 billion by 2025[2, 39] - Approximately 62,000 people are diagnosed with pancreatic cancer annually, and approximately 50,000 die from it annually[39] - There were approximately 19 million new solid tumor cases in the U S in 2022, leading to approximately 6 million solid tumor-related deaths[46] Collaboration and Intellectual Property - The company is collaborating with VolitionRX to develop proprietary adoptive cell therapies potentially targeting multiple solid cancer types[2, 58] - VolitionRX is expected to fund the research program, with both parties sharing proceeds from commercialization or licensing of any resulting products[60] - The company has an IP portfolio covering the co-administration of Systemic DNase I with ICIs, radiation, and chemo, as well as DNase I for pancreatic cancer and DNase I-secreting CAR T cells[62, 64]